logo-loader
THC Global Group Ltd

The Hydroponics Company supplies first Australian patients prescribed cannabidiol products

The company is building a strong supply chain in anticipation of the launch of its proprietary manufactured products in 2019.

1541123149_shutterstock_734579047.jpg
The medical cannabis company is vertically integrated from 'Farm-to-Pharma'

The Hydroponics Company Ltd (ASX:THC) has supplied Endoca cannabidiol (CBD) products to its first prescribed Australian patients.

The supply has verified THC’s product pathway from manufacturer through to patient under federal authorised prescriber and special access schemes, as well as relevant state regulations.

THC is currently importing four products from Endoca’s range: Endoca’s CBD oil in 3% and 15% concentrations; and Endoca’s unique CBD-plus-CBDa oils also in 3% and 15% concentrations.

THC is also preparing to change its company name to THC Global Group Limited, with a resolution to be put forward at the company’s annual general meeting on November 15.

READ: The Hydroponics Company well placed to grow as Canada set to legalise recreational cannabis

THC chief executive officer Ken Charteris said: “The ability to secure supply of high-quality GMP-certified medicinal cannabis products to domestic patients is a key bridge to implementation of THC Global’s ‘Farm-to-Pharma’ model.

“We continue to build out our domestic infrastructure in Australia under our Farm-to-Pharma model – research, growing, manufacture and supply.”

 

READ: The Hydroponics Company to change name to THC Global Group Limited

THC is building patient and prescriber awareness including sponsoring educational events to highlight the benefits of treatment with medicinal cannabis and the pathways to access the product in Australia.

As awareness increases within the domestic market, THC expects to see corresponding increases in revenue-generating product sales.

The company has also made available documentation for doctors and other prescribers to assist in prescribing Endoca’s products in Australia under the authorised prescriber and special access schemes.

Quick facts: THC Global Group Ltd

Price: $0.48

Market: ASX
Market Cap: $65.15 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of THC Global Group Ltd named herein, including the promotion by the Company of THC Global Group Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

THC Global obtains manufacturing licence for Southport cannabis facility

THC Global Group Limited (ASX:THC) chief executive officer Ken Charteris talks to Proactive Investors about receiving a medicinal cannabis manufacturing licence at its large Southport manufacturing facility on Queensland's Gold Coast. The licence is required for the commercial production...

on 9/7/19

2 min read